Jeff Yass’s Outlook Therapeutics OTLK Stock Holding History

Jeff Yass’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$862K	Buy	+542,200	New	+$336K	﹤0.01%	8574
2026 Q1	–	Sell	-367,800	Closed	-$581K	–	13856
2025 Q4	$581K	Buy	+367,800	New	+$588K	﹤0.01%	8442
2025 Q1	–	Sell	-21,200	Closed	-$40.1K	–	13196
2024 Q4	$40.1K	Sell	21,200 -21,000	-50%	-$86.4K	﹤0.01%	11762
2024 Q3	$225K	Buy	42,200 +29,100	+222%	+$213K	﹤0.01%	10220
2024 Q2	$96.7K	Buy	+13,100	New	+$105K	﹤0.01%	11050

Other funds holding OTLK

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GWM

Gilpin Wealth Management Denver, Colorado $145M AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jeff Yass's OTLK Position: Q2 2026 in Review

Jeff Yass increased its Outlook Therapeutics (OTLK) stake by 622% in Q2 2026, buying an estimated $517K and bringing the position to 968,190 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #7096.

Jeff Yass first reported a position in OTLK in Q1 2018 and has held it in 20 quarters since. 70 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

Jeff Yass held 968,190 shares of Outlook Therapeutics worth $1.54M as of Q2 2026.
Jeff Yass bought 834,106 Outlook Therapeutics shares in Q2 2026, an estimated $517K.
Outlook Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #7096 holding.
Jeff Yass first reported a position in Outlook Therapeutics in Q1 2018 and has held it in 20 quarters since.
70 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.